The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phi-53: (NCI#7251): Phase I trial of belinostat (PXD101) in combination with 13-cis-retinoic acid (13c-RA) in advanced solid tumor malignancies—A California Cancer Consortium NCI/CTEP sponsored trial.
Thehang H. Luu
No relevant relationships to disclose
Paul Henry Frankel
No relevant relationships to disclose
Dean Lim
No relevant relationships to disclose
Mihaela C. Cristea
No relevant relationships to disclose
Jan Hendrik Beumer
No relevant relationships to disclose
Leonard Joseph Appleman
No relevant relationships to disclose
Heinz-Josef Lenz
No relevant relationships to disclose
David R. Gandara
No relevant relationships to disclose
Richard Piekarz
No relevant relationships to disclose
Edward M. Newman
No relevant relationships to disclose